However, aside from one study showing a positive response to AZD3965 treatment in xenograft models, specifically when lysine acetyltransferase 2A (KAT2A) was overexpressed, and MCT1 was upregulated, no clinical data demonstrate the response of this treatment in patients with ccRCC (Li X. et al., 2023; Guo et al., 2021). Here, KAT2A is linked to nonpapillary renal cell carcinoma.